Quick Answer
Enveric Biosciences, Inc. reported Net Income Loss of -$8.77 million for the year ending 2025.
- Enveric Biosciences, Inc. showed an increase of +8.4% in Net Income Loss from 2024 to 2025.
- This data is from Enveric Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2010 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: $5.70 million | Q1 2019: -$1.86 million | Q2 2019: -$1.26 million | Q3 2019: $41.3 thousand | Q1 2020: -$1.10 million | Q2 2020: -$818.4 thousand | Q3 2020: -$565.3 thousand | Q1 2021: -$3.25 million | Q2 2021: -$908.3 thousand | Q3 2021: -$2.71 million | Q1 2022: -$4.52 million | Q2 2022: -$2.79 million | Q3 2022: -$2.48 million | Q1 2023: -$4.68 million | Q2 2023: -$6.36 million | Q3 2023: -$2.82 million | Q1 2024: -$2.46 million | Q2 2024: -$1.88 million | Q3 2024: -$2.08 million | Q1 2025: -$2.18 million | Q2 2025: -$2.52 million | Q3 2025: -$1.87 million.
- Over the full 15 years of available data (2010 to 2025), Enveric Biosciences, Inc.'s Net Income Loss has declined by 22,140.8%.
- Historical annual values: Fiscal year 2025: -$8.77 million | Fiscal year 2024: -$9.57 million | Fiscal year 2023: -$17.29 million | Fiscal year 2022: -$18.47 million | Fiscal year 2021: -$48.98 million | Fiscal year 2020: -$6.86 million | Fiscal year 2019: -$2.41 million | Fiscal year 2018: -$16.90 million | Fiscal year 2017: -$9.07 million | Fiscal year 2016: -$2.78 million | Fiscal year 2014: -$33.6 thousand | Fiscal year 2013: -$161.00 | Fiscal year 2012: -$24.6 thousand | Fiscal year 2011: -$33.4 thousand | Fiscal year 2010: -$39.4 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: